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The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not
been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days)
and standard oral ganciclovir (1 g three times a day for 90 days, GCV) in preventing CMV disease in 109 adult liver transplant
recipients who survived at least 1 month between January 2001 and April 2003 (49 GCV and 60 VGCV). The incidence of CMV
disease at 1 year post-transplant was similar among patients treated with VGCV and GCV (3% and 4%, respectively). Three
of the four CMV disease cases occurred in high-risk recipients with CMV serotype of donor/recipient (D/R) and all cases
presented after completion of CMV prophylaxis, ranging 114-152 days post-transplant. Severe neutropenia was rare, and
thrombocytopenia and anemia occurred at similar frequencies with both prophylaxis regimens. In conclusion, a 90-day regimen
of low-dose oral VGCV has a similar efficacy and safety profile to high-dose oral GCV in adult liver transplant recipients.
D/R liver transplant recipients remain at risk of developing CMV disease after completion of antiviral prophylaxis. Additional
prospective studies with close monitoring for CMV viremia and drug resistance are needed to further establish the optimal dose
and duration of VGCV in liver transplant recipients. Liver Transpl 12:112–116, 2006. © 2005 AASLD.
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Cytomegalovirus (CMV) infection accounts for significant
morbidity and mortality in solid organ transplant recipi-
ents. It can not only cause tissue-invasive infection in
immunocompromised hosts but may also be associated
with allograft injury, rejection, opportunistic infections,
and development of malignancy via immune-modulating
effects.1 Ganciclovir (GCV) has been widely used to pre-
vent CMV disease post-transplant since it was introduced
in 1989.2-7 However, oral GCV has poor bioavailability
and requires high-dose frequent administration and in-
travenous GCV is costly and inconvenient, requiring long-
term intravenous access.
Valganciclovir (VGCV) is the valine ester prodrug of
GCV, which has markedly improved oral bioavailabil-
ity compared to GCV (60% vs. 6%).8 Oral VGCV given
as 450 mg per day offers convenient once-daily
dosing while delivering systemic GCV exposure equiv-
alent to that of oral GCV 1 g three times a day.8
To date, the safety and efficacy of VGCV in liver
transplant recipients has not been established.9,10
The aim of this study was to compare our experience
with low-dose oral VGCV (450 mg once daily) for
CMV prophylaxis in consecutive adult liver trans-
plant recipients who survived at least 1 year post-
transplant to that of standard oral GCV (1 g three
times a day).
METHODS
Patient Population and Study Design
We retrospectively reviewed medical records of all pa-
tients  18 years of age who underwent orthotopic,
cadaveric liver transplantation at the University of
Michigan between January 2001 and April 2003. A
waiver of consent was obtained from the Institutional
Review Board.
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Outcome Measures
Data retrieved from the medical records included pa-
tient demographics, CMV serotype of donor and recip-
ient (D/R), CMV prophylactic regimen, quantitative
CMV-DNA by polymerase chain reaction (PCR) results,
immunosuppression regimen, biopsy results, and he-
matological labs during the first year post-transplant.
At our transplant center, medication profiling and lab-
oratory monitoring were routinely performed at least
once a week in the first month following liver transplan-
tation and at least once a month thereafter.
For the efficacy analysis, the primary outcome mea-
sure was the incidence of CMV disease within 1 year
post-transplant. CMV disease was defined as the detec-
tion of CMV by quantitative CMV-DNA PCR (detection
limit 600 copies/mL) in the blood accompanied either
by “CMV syndrome” (fever, malaise, or leucopenia) or by
organ dysfunction in the absence of other documented
causes. At our transplant center, CMV-DNA PCR and
biopsy were only performed when clinically indicated.
The diagnosis of CMV infection and disease has evolved
considerably in the past decade, yet significant varia-
tions exist in definitions of CMV infection and disease
that have been used in both research and clinical set-
tings.9,11-13 The criteria we used for CMV disease are
similar to that used in other published studies.11–13
Secondary safety outcomes in our study included the
incidence of hematological side effects in the GCV and
VGCV groups, including severe neutropenia (absolute
neutrophil count 500/mm3), thrombocytopenia
(platelet  100,000/mm3), and anemia (hemoglobin 
8.0 g/dL) during post-operative days 15-90. Hemato-
logical abnormalities from post-operative days 0-14
were excluded to avoid potential bias from end-stage
liver disease and blood loss during the early post-trans-
plant period.
Immunosuppression and CMV Prophylaxis
Most patients received triple immunosuppression with
tacrolimus, mycophenolate mofetil, and corticoste-
roids. Tacrolimus was started as 0.05 mg/kg orally
twice a day and the dose was adjusted to maintain
trough concentrations 12-15 ng/mL for the first month,
8-12 ng/mL for the second month, and 4-8 ng/mL
thereafter. Mycophenolate mofetil was given 1 g orally
twice a day and reduced for myelotoxicity and with-
drawn after 6 months in selected patients with hepatitis
C. Corticosteroids were initiated intraoperatively with
500 mg of intravenous methylprednisolone, followed by
intravenous methylprednisolone or equivalent oral
prednisone taper to 30 mg/day by post-operative day 6
and gradually decrease to stop by 3 to 6 months. Cor-
ticosteroid use was completely avoided in 5 patients
who were enrolled in a steroid-free protocol in the VGCV
arm, while using the same tacrolimus and mycopheno-
late mofetil regimen. Episodes of biopsy proven acute
cellular rejection were treated with 500 mg of intrave-
nous methylprednisolone for three days along with a
steroid taper. Steroid-resistant or severe rejection was
treated with intravenous muromonab-CD3 5 mg/dose
or rabbit anti-thymocyte globulin 1.5 mg/kg/dose for
7-14 days.
All patients except for D/R patients received CMV
prophylaxis for 90 days post-transplant and after the
antibody therapy for rejection. Oral GCV 1 g three times
a day was used until March 15, 2002. Thereafter, our
prophylaxis protocol was changed to oral VGCV 450 mg
once daily. Doses of both drugs were reduced for im-
paired renal function per manufacturers guidelines.
D/R; patients received oral acyclovir 400 mg twice a
day for herpes prophylaxis for 30 days post-transplant
and were not included in this analysis.
Statistical Analysis
Two-sample t-test for continuous variables and Fisher’s
exact test for binomial proportions were used to com-
pare differences between GCV and VGCV groups. In all
tests, two-sided p-values less than 0.05 were consid-
ered to be significant.
RESULTS
Patient Characteristics
Between January 2001 and April 2003, 148 adult liver
transplants were performed in 145 patients at the Uni-
versity of Michigan. Thirty-nine transplants in 37 pa-
tients were excluded for the following reasons: 13 died
or had re-transplant 1 month post-transplant; 20 re-
ceived acyclovir for D/R status; five received an in-
vestigational antiviral agent for CMV prophylaxis; and
one had a prior kidney transplant. None of the 13 pa-
tients (three GCV treated and 10 VGCV treated pa-
tients) who were excluded for death or re-transplant 
1 month post-transplant experienced CMV disease dur-
ing their follow-up. The remaining 109 liver transplants
were used for the final data analysis. One-year fol-
low-up data were available for 96% of GCV patients
(85-365 days) and 88% of VGCV patients (31-365 days).
The characteristics of patients in the two study
groups are summarized in Table 1. Of note, the distri-
bution of CMV D/R serotypes was similar in the two
groups as well as the duration of CMV prophylaxis. The
rates and treatment for acute cellular rejection were
also similar in the two groups.
CMV Disease
The overall incidence of CMV disease within 1 year
post-transplant was low (3.7%) in high to moderate risk
liver transplant recipients (D or R) when either oral
GCV or low-dose VGCV prophylaxis was used. The in-
cidence of CMV disease was similar between the GCV
and the low-dose VGCV groups (4% and 3%, respec-
tively) (Table 2). All but one case occurred in patients
with high risk CMV serotype (D/R; 7% with VGCV
and 22% with GCV, p  0.533) and all cases developed
after completion of the 90 day CMV prophylaxis, at a
median of 133 days post-transplant (range, 114-152
days). One patient in the VGCV group (V-2) received
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steroid pulse treatment for rejection 4 months prior to
the onset of CMV disease. Patient G-1 was treated with
intravenous GCV 5 mg/kg twice daily for two months
followed by oral VGCV 450 mg daily for another month.
Three patients (G-2, V-1, and V-2) were treated for their
CMV disease with VGCV 900 mg twice daily for three
weeks. Patients G-1, G-2, and V-2 cleared viremia on
repeat CMV-PCR testing during the antiviral treatment.
Follow-up virological testing was not available for pa-
tient V-1. None of the CMV disease cases experienced
recurrent CMV disease during the first year post-trans-
plant (Table 3). An additional patient receiving VGCV
developed CMV viremia (73,100 copies/mL) at 261 days
post-transplant without documented CMV syndrome or
organ dysfunction. This patient did not require antiviral
therapy or experience further viral infectious complica-
tions throughout the 1 year follow-up period.
Hematological Side Effects
The hematological side effect profile of VGCV was sim-
ilar to that of GCV. Severe neutropenia was uncommon
with both low-dose VGCV and GCV (2% and 0%, re-
spectively). There was a trend toward higher incidences
of thrombocytopenia and anemia in the low-dose VGCV
group compared to the GCV group, but the differences
were not statistically significant (Table 4).
DISCUSSION
Although the efficacy and safety of VGCV in CMV pro-
phylaxis is well documented in other types of solid or-
gan transplantation, it has not been established in liver
transplant recipients.9-12 In a randomized double-blind
controlled study of high-risk solid organ transplant re-
cipients (D/R), oral VGCV 900 mg once daily for 100
days was as effective as oral GCV 1 g three times a day





Age, mean  SD (years) 50  10 49  10
Gender, no. (%) of patients
Male 27 (55%) 42 (70%)
Female 22 (45%) 18 (30%)
Race, noumber (%) of patients
Caucasian 44 (90%) 53 (88%)
Black 1 (2%) 3 (5%)
Other 4 (8%) 4 (7%)
Primary liver disease†
Hepatitis C 15 (31%) 29 (48%)
Alcoholic liver disease 8 (16%) 11 (18%)
Hepatitis B 7 (14%) 1 (2%)
Cryptogenic cirrhosis 3 (6%) 4 (7%)
Primary biliary cirrhosis 4 (8%) 2 (3%)
Autoimmune hepatitis 3 (6%) 2 (3%)
Primary sclerosing cholangitis 2 (4%) 7 (12%)
Other 7 (14%) 4 (7%)
CMV serotype, number (%) of patients
D/R 9 (18%) 15 (25%)
D/R 24 (49%) 25 (42%)
D/R 16 (33%) 20 (33%)
Duration of CMV prophylaxis, mean  SD (days) 90  26 81  20
Re-transplant, number of patients 0 1
Deaths from 1 to 12 months 2 7
Steroid-free immunosuppression, number of patients 0 5
Biopsy-proven rejection, no. (%) of patients 15 (31%) 13 (22%)
Steroid treated 13 12
r-ATG treated 2 1
Abbreviations: SD, standard deviation; CMV, cytomegalovirus; D, donor; R, recipient; r-ATG, rabbit anti-thymocyte globulin.
*P-values for all items  0.05
†Owing to rounding, percentages do not total 100.
TABLE 2. Incidence of Cytomegalovirus Disease
within 1 Year Post-Transplant
Ganciclovir Valganciclovir P-value
Overall 2/49 (4%) 2/60 (3%) NS
D/R 2/9 (22%) 1/15 (7%) NS
D/R 0/24 (0%) 1/25 (4%) NS
D/R 0/16 (0%) 0/20 (0%) NS
Abbreviations: D, donor; R, recipient; NS, not significant.
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during the first year post-transplant.9 When data from
the liver transplant subgroup were analyzed, there was
no statistical difference in the overall incidence of CMV
disease at 6-month post-transplant between the GCV
group and the VGCV group (12% vs. 19%). However,
significantly more patients in the VGCV group devel-
oped tissue-invasive disease compared to the GCV
group (14% vs. 3%, P  0.037).10 Based on these find-
ings, VGCV was approved by the U.S. Food and Drug
Administration for use as CMV prophylaxis in high-risk
kidney, heart, and kidney-pancreas transplant recipi-
ents but not in liver transplant recipients.
Because oral VGCV 450 mg once daily yields a similar
area under the GCV concentration-time curve as oral
GCV 1 g three times a day, it was proposed that low-
dose VGCV (450 mg once daily) may be as efficacious as
the standard oral GCV (1 g three times a day) in CMV
prophylaxis while offering convenient once daily dosing
and improved patient compliance.8 Promising clinical
outcomes of low-dose VGCV prophylaxis have been
documented in kidney transplant recipients including
high-risk patients (D/R).11–13 Based on these data,
we felt it would be reasonable to offer low-dose oral
VGCV to our adult liver transplant recipients and then
compare the rates of CMV disease to a historic control
group of GCV treated patients.
Our retrospective analysis suggests that low-dose
VGCV (450 mg once daily for 90 days) is as effective as
the standard oral GCV (1 g three times a day) in pre-
venting CMV disease in adult liver transplant recipients
who survive  1 month post-transplant. The overall
incidence of CMV disease with both prophylactic regi-
mens was low (4% with the GCV and 3% with the VGCV)
and comparable to what was previously reported with
the standard oral GCV (4.8%).3 During our study pe-
riod, most patients received tacrolimus, mycophenolate
mofetil, and prednisone and 5 patients in the low-dose
VGCV group received a steroid-free regimen. Regarding
safety, the incidence of severe neutropenia, anemia,
and thrombocytopenia was similar with GCV and VGCV
in our study.
Potential limitations of our study include its retro-
spective nature, the lack of standardized monitoring for
CMV viremia, and the small sample size. Although our
study has a historic control group of GCV-treated pa-
tients, the clinical and disease characteristics of the
patients were similar to the VGCV treated patients (Ta-
ble 1). The immunosuppressive protocol was consistent
over time as well. More importantly, the CMV D/R se-
rotype distributions and duration of CMV prophylaxis
were similar in the two treatment groups. In our center,
CMV viremia is not prospectively monitored due to the
low rate of CMV disease we have encountered in the
past. In addition, recent studies demonstrate a poor
correlation between CMV viremia and development of
CMV disease.14 Although we could not determine if the
rates of CMV viremia were substantially different be-
tween the two prophylaxis regimens, it should be noted
that our results of identifying CMV disease primarily
amongst high-risk individuals (D/R) and the overall
low 1 year incidence of CMV disease is similar to other
published studies.3–7 Only a prospective, randomized
controlled study with serial monitoring of CMV viremia,
symptoms and signs of organ dysfunction would be
able to compare the rates of CMV infection and disease.
Our data show that CMV disease continues to be
prevalent in D/R liver transplant recipients despite
prophylaxis as reported in prior studies.3–7 As noted in
prior studies of kidney transplant recipients, most CMV
disease cases occurred after completion of CMV pro-
phylaxis with either VGCV or GCV.11-13 Proposed strat-
egies to decrease the incidence of CMV disease in the
TABLE 3. Summary of Cytomegalovirus Disease Cases









G-1 GCV D/R 133 95,900 Hepatitis GCV IV followed
by VGCV
G-2 GCV D/R 152 37,100 Fever VGCV
V-1 VGCV D/R 114 Not available Gastritis VGCV
V-2 VGCV D/R 132 64,300 Malaise VGCV
Abbreviations: CMV, cytomegalovirus; POD, post-operative day; GCV, ganciclovir; VGCV, valganciclovir; D, donor; R,
recipient; IV, intravenous.





Neutropenia (Absolute neutrophil count  500/mm2) 1 (2%) 0 (0%)
Thrombocytopenia (Platelet  100,000/mm2) 8 (16%) 13 (22%)
Anemia (hemoglobin  8.0 g/mL) 1 (2%) 4 (7%)
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high-risk group include high-dose VGCV (e.g., 900 mg/
day) and a longer duration of therapy (e.g., 6
months).9,13,15 Paya et al. reported that CMV disease
developed within 6 months post-transplant in 19% of
the high-risk liver transplant recipients who received
100 days of VGCV 900 mg/day.9 In our study, CMV
disease developed in 7% of the same risk group at
1-year post-transplant when 90 days of VGCV 450 mg/
day was used. Because Paya et al. used more strict
criteria to define CMV disease (positive CMV-DNA PCR,
fever on two occasions at least 24 hours apart, and one
or more signs or symptoms of CMV infection), the inci-
dence could have been even higher if the criteria used in
our study had been applied. However, the reported in-
cidence rates cannot be compared directly because of
different CMV disease criteria, follow-up periods, and
study designs. In kidney transplant recipients, low-
dose VGCV prophylaxis for 6 months has been used
with success in high risk groups (D/R or rabbit anti-
thymocyte globulin treated patients).13,15 Currently,
there are no data to support using VGCV 450 mg/day
for more than 3 months in liver transplant recipients,
which may be associated with greater hematological
toxicity, cost, and potential resistance.
With the increased use of GCV or VGCV for CMV
prophylaxis in solid organ transplant recipients, con-
cerns for emergence of GCV-resistant CMV have been
raised. It has been proposed that the relatively low GCV
serum concentrations achieved with oral GCV and low-
dose VGCV for prolonged periods may lead to the selec-
tion of GCV-resistant CMV mutants.16 However, GCV-
resistant CMV mutants were better documented in
patients receiving GCV.16,17 Although there is no evi-
dence thus far that demonstrates an increased risk of
drug-resistant CMV with using low-dose or full-dose
VGCV, this should be clarified in a larger popula-
tion.11,13,18 Although we did not perform GCV suscep-
tiblity tests in patients with CMV disease, all of our
patients responded clinically to GCV or VGCV therapy
without recurrence of CMV disease during follow-up.
In summary, our retrospective study suggests that
low-dose VGCV appears as efficacious and safe in the
prevention of CMV disease in adult liver transplant
recipients, as standard oral GCV. Our findings also
demonstrate the high risk of D/R patients devel-
oping symptomatic CMV disease within the first year
post-transplant after antiviral prophylaxis has been
discontinued. To better define the optimal CMV pro-
phylaxis regimen in adult liver transplantation, a
large clinical trial of VGCV compared to oral GCV with
stratified randomization for duration of therapy
based on CMV D/R serotype is recommended with
prospective assessment of CMV DNA levels and po-
tential drug resistance.
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